Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Louis Kayitalire"'
Autor:
Michelle Morrow, Deborah J Wong, Maxwell J Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J Shepherd, Louis Kayitalire
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Anaplastic thyroid cancer represents a rare, highly aggressive form of thyroid cancer with a poor prognosis and an overall survival ranging from 5 to 12 months. Unfortunately, treatment options remain limited, even for patients with a targetable driv
Externí odkaz:
https://doaj.org/article/a307d489f0144259ba45d1a43310d56f
Autor:
Timothy A. Yap, Patricia M. LoRusso, Deborah J. Wong, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leung, Sylwia Marshall, Claire S. Reader, Roslin Russell, Richard C.A. Sainson, Claire J. Seal, Christopher J. Shepherd, Fiona Germaschewski, Daniel Gliddon, Omer Stern, Lesley Young, Neil Brewis, Louis Kayitalire, Michelle Morrow
Publikováno v:
Clinical Cancer Research. 29:888-898
Purpose:This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody–targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti–PD-(L)1 therapy.Patient
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Supplementary Table S1: Representativeness of Study Participants.Supplementary Table S2: Immunogenicity in patients treated with FS118.Supplementary Table S3: PK of FS118 by Dose Level.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e7c2e048ad7d481d58db7e5f5c9dae
https://doi.org/10.1158/1078-0432.22489940
https://doi.org/10.1158/1078-0432.22489940
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Supplementary information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b184e3f77517649b8130a606ef0a05
https://doi.org/10.1158/1078-0432.22489943
https://doi.org/10.1158/1078-0432.22489943
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Supplementary Figure S1: Study design for the evaluation of FS118 in subjects with advanced solid tumors whoprogressed on or after prior PD-(L)1 therapy.Supplementary Figure S2: Time on FS118 treatment in patients with primary or acquired resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b19bd1e4fc2bc411e31a1ea30e2ba5
https://doi.org/10.1158/1078-0432.22489946.v1
https://doi.org/10.1158/1078-0432.22489946.v1
Autor:
Michelle Morrow, Louis Kayitalire, Neil Brewis, Lesley Young, Omer Stern, Daniel Gliddon, Fiona Germaschewski, Christopher J. Shepherd, Claire J. Seal, Richard C.A. Sainson, Roslin Russell, Claire S. Reader, Sylwia Marshall, Kin-Mei Leung, Cristian Gradinaru, Urszula Grabowska, Josefin-Beate Holz, Kyriakos P. Papadopoulos, Siwen Hu-Lieskovan, Deborah J. Wong, Patricia M. LoRusso, Timothy A. Yap
Purpose:This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody–targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti–PD-(L)1 therapy.Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b08ea5484c59f0d44d3a336fb85f05b3
https://doi.org/10.1158/1078-0432.c.6533066
https://doi.org/10.1158/1078-0432.c.6533066
Autor:
Maxwell J Kroloff, Josefin-Beate Holz, Omer Stern, Christopher J Shepherd, Michelle Morrow, Louis Kayitalire, Deborah J Wong
Publikováno v:
Journal for immunotherapy of cancer, vol 10, iss 10
Anaplastic thyroid cancer represents a rare, highly aggressive form of thyroid cancer with a poor prognosis and an overall survival ranging from 5 to 12 months. Unfortunately, treatment options remain limited, even for patients with a targetable driv
Autor:
Pascal, Hammel, Jill, Lacy, Fabienne, Portales, Alberto, Sobrero, Beatriz, García-Paredes, Edward, Kim, Fernando, Rivera, Luis, Manzano Jose, Eric, Terrebonne, Venu, Bathini, Scot, Dowden, Jamil, Asselah, Jack, Shiansong Li, Thomas, Nydam, Louis, Kayitalire, Philip, Philip
Publikováno v:
In Annals of Oncology June 2016 27 Supplement 2:ii78-ii78
Autor:
Elsa Vanhecke, Elisabeth Brambilla, Philippe Vielh, Angélique Robin, Louis Kayitalire, Julien Adam, Robert Pirker, Thierry Le Chevalier, Jean-Charles Soria, Helmut Popper, Luc Friboulet, Martin Filipits, Ken A. Olaussen, Jürgen Thomale, Frédéric Commo, Fabrice Andre
Publikováno v:
Lung Cancer; Vol 80
Lung Cancer
Lung Cancer
Evaluation of DNA repair proteins might provide meaningful information in relation to prognosis and chemotherapy efficacy in Non-Small Cell Lung Cancer (NSCLC) patients. The role of Poly(ADP-Ribose) Polymerase (PARP) in DNA repair of platinum adducts